Advertisement

ADVERTISEMENT

Katie Herman

Conference Coverage
Quality of Care and Research Initiatives in the Enhancing Oncology Model
10/15/2022
Lee A. Fleisher, MD, CMS Chief Medical Officer, Director, Center for Clinical Standards and Quality, presented data at the 2022 Oncology Clinical Pathways Congress regarding the Oncology Care Model as well as the development plan for the...
Lee A. Fleisher, MD, CMS Chief Medical Officer, Director, Center for Clinical Standards and Quality, presented data at the 2022 Oncology Clinical Pathways Congress regarding the Oncology Care Model as well as the development plan for the...
Lee A. Fleisher, MD, CMS Chief...
10/15/2022
Journal of Clinical Pathways
Conference Coverage
High-Risk Lesions: A Consistent Predictor of Ultra-High Risk Multiple Myeloma
12/11/2022
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
Martin F Kaiser, MD, FRCP,...
12/11/2022
Journal of Clinical Pathways
Conference Coverage
The State of Clinical Pathways – 2022 Survey Results
10/15/2022
The Journal of Clinical Pathways’ Editor-in-Chief, Winston Wong, PharmD, presented results from the publication’s 5th annual benchmarking survey at the 2022 Oncology Clinical Pathways Congress, stating a trend in increased demand for improved...
The Journal of Clinical Pathways’ Editor-in-Chief, Winston Wong, PharmD, presented results from the publication’s 5th annual benchmarking survey at the 2022 Oncology Clinical Pathways Congress, stating a trend in increased demand for improved...
The Journal of Clinical...
10/15/2022
Journal of Clinical Pathways
Conference Coverage
Molecular Variants Associated With Resistance to a Quadruplet Treatment Combination in Newly Diagnosed Multiple Myeloma
12/11/2022
At the 2022 ASH Annual Meeting, Francesco Maura, MD, and colleagues investigated the molecular variants associated with resistance to a quadruplet treatment combination in patients with newly diagnosed multiple myeloma.
At the 2022 ASH Annual Meeting, Francesco Maura, MD, and colleagues investigated the molecular variants associated with resistance to a quadruplet treatment combination in patients with newly diagnosed multiple myeloma.
At the 2022 ASH Annual Meeting,...
12/11/2022
Journal of Clinical Pathways
Conference Coverage
ePROs Effect on Patient Health Outcomes
10/17/2022
Michael Kolodziej, MD, Senior Advisor, ADVI, presented that patient monitoring during treatment using electronic patient-reported outcomes significantly improves results.
Michael Kolodziej, MD, Senior Advisor, ADVI, presented that patient monitoring during treatment using electronic patient-reported outcomes significantly improves results.
Michael Kolodziej, MD, Senior...
10/17/2022
Journal of Clinical Pathways
Conference Coverage
Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma
12/10/2022
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
CancerLinQ Technology in the Oncology Community
10/17/2022
Robert S. Miller, MD, FACP, FASCO, FAMIA, Chief Medical Science Officer, CancerLinQ, American Society of Clinical Oncology, described how data aggregation and analytic platforms are aiding in clinical decision support and explained current...
Robert S. Miller, MD, FACP, FASCO, FAMIA, Chief Medical Science Officer, CancerLinQ, American Society of Clinical Oncology, described how data aggregation and analytic platforms are aiding in clinical decision support and explained current...
Robert S. Miller, MD, FACP,...
10/17/2022
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness Analyses of Ibrutinib vs Acalabrutinib vs Zanubrutinib as First-line Treatment in Patients With Chronic Lymphocytic Leukemia
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Therapeutic Interchange Reduces Cost While Maintaining Quality of Care in the US Oncology Care Model
10/01/2022
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care Symposium, Ives and colleagues concluded that therapeutic interchange is an effective way to reduce total cost of care while maintaining the quality of care in the Oncology Care Model.
At the 2022 ASCO Quality Care...
10/01/2022
Journal of Clinical Pathways
Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

Derm Week
November 13 ⁠–⁠ November 16
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use